Evidence map›Paper›PMID 34070045›Full record

ArticleCancers2021

The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus.

Anna C Lefèvre, Niels Pallisgaard, Camilla Kronborg, Karen L Wind, Søren R P Krag, Karen-Lise G Spindler

Registry-linked trialAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06640283 (Dynamic Assessment of ctDNA in Patients With Cervical and Anal Canal Tumors to Optimize Follow-up and Clinical Outcomes in the Brazilian Unified Health System), which is not on this map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06640283 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Dynamic Assessment of ctDNA in Patients With Cervical and Anal Canal Tumors to Optimize Follow-up and Clinical Outcomes in the Brazilian Unified Health System (SUS)

TypeinterventionalSponsorInstituto do Cancer do Estado de São PauloRan2025 to 2027Enrolled150ConditionsHPV-Related Carcinoma, Uterine Cervical Cancer, Anal Canal Cancer, HPV-Related Anal Squamous Cell CarcinomaArmsctDNA test, Pembrolizumab
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. The prognostic value of methylated ctDNA, soluble PD-L1, and NK-cell activity on the risk of relapse after curative radiotherapy of non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna C LefèvreExperimental Clinical Oncology, Aarhus University Hospital, 8200 Aarhus N, Denmark.ORCID 0000-0002-2937-4677
Niels PallisgaardDepartment of Pathology, Zealand University Hospital, 4000 Roskilde, Denmark.
Camilla KronborgDanish Centre for Particle Therapy, 8200 Aarhus N, Denmark.
Karen L WindExperimental Clinical Oncology, Aarhus University Hospital, 8200 Aarhus N, Denmark.
Søren R P KragDepartment of Pathology, Aarhus University Hospital, 8200 Aarhus N, Denmark.
Karen-Lise G SpindlerExperimental Clinical Oncology, Aarhus University Hospital, 8200 Aarhus N, Denmark.

Funding

Aarhus UniversitetshospitalBio- and Genome Bank DenmarkDanish Comprehensive Cancer Center - RadiotherapyKræftens Bekæmpelse
6 · The paper itself

Abstract

background and purposeCirculating tumor DNA (ctDNA) is investigated in various cancers. In squamous cell carcinoma of the anus (SCCA) infection with human papilloma virus (HPV) is found in around 90% of cases and here, plasma HPV (pHPV) can be used as ctDNA. Preliminary data have proved the ability to detect pHPV16 and -18 in SCCA. We have developed a highly sensitive method for measurement of six relevant pHPV subtypes, to investigate the elimination pattern of pHPV during chemo-radiotherapy (CRT) for SCCA and its clinical value. MATERIAL AND

methodsPatients treated at Aarhus University Hospital from 2016-2020 were included. P16 status in the primary biopsy was measured and 82% of patients had P16 positive tumor. Blood samples were collected prior to treatment (PT), mid treatment (MT), end of therapy (EOT), and during follow-up (FU). An in-house multiplex digital droplet PCR method measured pHPV subtypes 16, 18, 31, 33, 51, 58.

resultsSamples from 88 patients were drawn PT (

conclusionDuring CRT, pHPV can divide patients with SCCA into three groups with significantly different risk of failure. The use of pHPV can potentially assist in clinical treatment decision.

Indexed as

anus neoplasmscirculating tumor DNAhuman papillomavirussquamous cell carcinoma

Identifiers

PMID34070045
PMCPMC8158133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.